Association Study between Genetic Polymorphisms of CYP2C19 Gene and Essential Hypertension in Koreans |
Park, Ah-Ram
(Cardiovascular Genome Center, Yonsei University College of Medicine)
Shin, Eun-Soon (DNA Link Inc.) Son, Nak-Hoon (Cardiovascular Genome Center, Yonsei University College of Medicine) Jang, Yang-Soo (Cardiovascular Genome Center, Yonsei University College of Medicine) Shin, Dong-Jik (Cardiovascular Genome Center, Yonsei University College of Medicine) |
1 | Goldstein, J. A., T. Ishizaki, K. Chiba, S. M. de Morais, D. Bell, P. M. Krahn, and D. A. Evans. 1997. Frequencies of the defective CYP2C19 alleles responsible for the mephenytoin poor metabolizer phenotype in various Oriental, Caucasian, Saudi Arabian and American black populations. Pharmacogenetics 7, 59-64. DOI ScienceOn |
2 | Gray, I. C., C. Nobile, R. Muresu, S. Ford, and N. K. Spurr. 1995. A 2.4-megabase physical map spanning the CYP2C gene cluster on chromosome 10q24. Genomics 28, 328-332. DOI ScienceOn |
3 | Harrap, S. B. 1994. Hypertension: genes versus environment. Lancet 344, 169-171. DOI ScienceOn |
4 | Herrlin, K., A. Y. Massele, M. Jande, C. Alm, G. Tybring, Y. A. Abdi, A. Wennerholm, I. Johansson, M. L. Dahl, L. Bertilsson, and L. L. Gustafsson. 1998. Bantu Tanzanians have a decreased capacity to metablolize omeprazole and mephenytoin in relation to their CYP2C19 genotype. Clin. Pharmacol. Ther. 64, 391-401. DOI ScienceOn |
5 | Aynacioglu, A. S., C. Sachse, A. Bozkurt, S. Kortunay, M. Nacak, T. Schroder, S. O. Kayaalp, I. Roots, and J. Brockmoller. 1999. Low frequency of defective alleles of cytochrome P450 enzymes 2C19 and 2D6 in the Turkish population. Clin. Pharmacol. Ther. 48, 409-415. |
6 | Bae, Y., C. Park, J. Han, Y. J. Hong, H. H. Song, E. S. Shin, J. E. Lee, B. G. Han, Y. Jang, D. J. Shin, and S. K. Yoon. 2007. Interaction between GNB3 C825T and ACE I/D polymorphisms in essential hypertension in Koreans. J. Hum. Hypertens. 21, 159-166. DOI ScienceOn |
7 | Bertrand-Thiebault, C., H. Berrahmoune, A. Thompson, B. Marie, S. Droesch, G. Siest, D. Foernzler, and S. Visvikis-Siest. 2008. Genetic polymorphisms of CYP2C19 gene in the Stanislas Cohort. A link with inflammation. Ann. Hum. Genet. 72, 178-183. DOI ScienceOn |
8 | Chen, L., S. Qin, J. Xie, J. Tang, L. Yang, W. Shen, X. Zhao, J. Du, G. He, G. Feng, L. He, and Q. Xing. 2008. Genetic polymorphisms analysis of CYP2C19 in Chinese Han populations from different geographic areas of mainland China. Pharmacogenomics 9, 691-702. DOI ScienceOn |
9 | Yamada, S., M. Onda, S. Kato, N. Matsuda, T. Matsuhisa, N. Yamada, M. Miki, and N. Matsukura. 2001. Genetic differences in CYP2C19 single nucleotide polymorphisms among four Asian populations. J. Gastroenterol. 36, 696-699. DOI ScienceOn |
10 | Xie, H. G., C. M. Stein, R. B. Kim, G. R. Wilkinson, D. A. Flockhart, and A. J. Wood. 1999. Allelic, genotypic distributions of S-mephenytoin 4’-hydroxylase (CYP2C19) in healthy Caucasian populations of European descent throughout the world. Pharmacogenetics 9, 539-549. DOI ScienceOn |
11 | Zand, N., N. Tajik, A. S. Moghaddam, and I. Milanian. Genetic polymorphisms of cytochrome P450 enzymes 2C9 and 2C19 in a healthy Iranian population. Clin. Exp. Pharmacol. Physiol. 34, 2-5. |
12 | Rahman, M., J. T. Wright, and J. G. Douglas. 1997. The role of cytochrome P450 dependent metabolites of arachidonic acid in blood pressure regulation and renal function. Am. J. Hypertens. 10, 356-365. DOI ScienceOn |
13 | Lee, S. S., S. J. Lee, J. Gwak, H. J. Jung, H. Thi-Le, I. S. Song, E. Y. Kim, and J. G. Shin. 2007. Comparisons of CYP2C19 genetic polymorphisms between Korean and Vietnamese populations. Ther. Drug Monit. 29, 455-459. DOI ScienceOn |
14 | Lee, J. M., S. H. Park, D. J. Shin, D. H. Choi, C. Y. Shim, Y. G. Ko, J. S. Kim, E. S. Shin, C. W. Chang, J. E. Lee, and Y. S. Jang. 2009. Relation of genetic polymorphisms in the cytochrome P450 gene with Clopidogrel resistance after drug-eluting stent implantation in Koreans. Am. J. Cardiol. 104, 46-51. DOI ScienceOn |
15 | Ozawa, S., A. Soyama, M. Saeki, H. Fukushima-Uesaka, M. Itoda, S. Koyano, Y. Ohno, Y. Saito, and J. Sawada. 2004. Ethnic differences in genetic polymorphisms of CYP2D6, CYP2C19, CYP3As and MDR1/ABCB1. Drug Metab. Pharmacokinet. 17, 150-156. |
16 | Roh, H. K., M. L. Dahl, G. Tybring, H. Yamada, Y. N. Cha, and L. Bertilsson. 1996. Debrisoquine and S- mephenytoin hydroxylation phenotypes and genotypes in a Korean population. Pharmacogenetics 6, 441-447. DOI ScienceOn |
17 | Scordo, M. G., A. P. Caputi, C. D’Arrigo, G. Fava, and E. Spina. 2004. Allele and genotype frequencies of CYP2C9, CYP2C19 and CYP2D6 in an Italian population. Pharmacol. Res. 50, 195-200. DOI ScienceOn |
18 | Turner, S. T., E. Boerwinkle, and C. F. Sing. 1999. Context-dependent associations of the ACE I/D polymorphism with blood pressure. Hypertension 34, 773-778. DOI |
19 | Taguchi, M., T. Nozawa, K. Mizumaki, H. Inoue, K. Tahara, C. Takesono, and Y. Hashimoto. 2004. Nonlinear mixed effects model analysis of the pharmacokinitics of metoprolol in routinely treated Japanese patients. Biol. Pharm. Bull. 27, 1642-1648. DOI ScienceOn |
20 | Tassaneeyakul, W., W. Mahatthanatrakul, K. Niwatananun, K. Na-Bangchang, A. Tawalee, N. Krikreangsak, U. Cykleng, and W. Tassaneeyakul. 2006. CYP2C19 genetic polymorphism in Thai, Burmese and Karen populations. Drug Metab. Pharmacokinet. 21, 286-290. DOI ScienceOn |
21 | De Morais, S. M., G. R. Wilkinson, J. Blaisdell, U. A. Meyer, K. Nakamura, and J. A. Goldstein. 1994. Identification of a new genetic defect responsible for the polymorphism of (S)-mephenytoin metabolism in Japanese. Mol. Pharmacol. 46, 594-598. |
22 | De Morais, S. M., G. R. Wilkinson, J. Blaisdell, K. Nakamura, U. A. Meyer, and J. A. Goldstein. 1994. The major genetic defect responsible for the polymorphism S-mephenytoin metabolism in humans. J. Biol. Chem. 269, 15419-15422. |
23 | Friedewald, W. T., R. I. Levy, and D. S. Fredrickson. 1972. Estimation of concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. Clin. Chem. 18, 499-502. |
24 | Fukushima-Uesaka, H., Y. Saito, K. Maekawa, S. Ozawa, R. Hasegawa, H. Kajio, N. Kuzuya, K. Yasuda, M. Kawamoto, N. Kamatani, K. Suzuki, T. Yanagawa, M. Tohkin, and J. I. Sawada. 2005. Genetic variations and haplotypes of CYP2C19 in a Japanese population. Drug Metab. Pharmacokinet. 20, 300-307. DOI ScienceOn |
25 | Goldstein, J. A. 2001. Clinical relevance of genetic polymorphisms in the human CYP2C subfamily. Br. J. Clin. Pharmacol. 52, 349-355. DOI ScienceOn |